Please Wait.....
Report
Human Insulin Market By Product Type (Pens, Syringes, Others), By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes) By Type of Insulin (Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, Others) By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Market Report I 2024-07-01 I 245 Pages I Allied Market Research
Human Insulin Market
Thehuman insulin marketwas valued at $17.1 billion in 2023and is projected to reach $24.0 billion by 2033, growing at a CAGR of 3.4% from 2024 to 2033.
Human insulin is a synthetic mimic of the natural peptide hormone, which is synthesized in laboratory settings inside E. coli bacteria. It exists in two forms: a short-acting regular form and an intermediate-acting form known as neural protamine Hagedorn insulin. Human insulin replaces the naturally produced insulin inside the body and regulates the glucose levels in the blood.
A key driver of the human insulin market is increase in the prevalence of diabetes globally. In addition, human insulin is experiencing a surge in demand from patients and medical practitioners as compared to animal insulin owing to its high efficacy and minimal risk of allergic reactions. The latest trend in the human insulin market is the inclination of patients toward biosimilar products owing to their comparable efficacy and high cost-effectiveness.
However, the presence of other alternatives such as oral medications and non-insulin injectables, including GLP-1 receptor agonists, offers a significant competition to human insulin. Moreover, the introduction of human insulin into the market is a complex & time-consuming process due to the lengthy regulatory approval procedure at different stages, which include pre-clinical stages, clinical trials, and post-market safety monitoring. This delays the availability of the protein, thereby limiting the development of the market. On the contrary, the integration of data-driven approaches such as AI and machine learning is expected to speed up production efficiency by optimizing the production parameters and predicting product yields.
Segment Review
The human insulin market is segmented into product type, indication, type of insulin, distribution channel, and region. On the basis of product type, the market is divided into pens, syringes, and others. As per indication, it is classified into type 1 diabetes, type 2 diabetes, and gestational diabetes. Depending on type of insulin, it is categorized into rapid-acting insulin, short-acting insulin, intermediate-acting insulin, and others. According to distribution channel, it is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of product type, the pens segment dominated the market in 2023.
As per indication, the type-1 diabetes segment acquired high stakes in the market in 2023.
Depending on type of insulin, the rapid-acting insulin segment garnered a high market sharein 2023.
According to distribution channel, the drug stores & retail pharmacies segment was the highest shareholder in 2023.
Region wise, North America was the highest revenue generator in 2023.
Competition Analysis
The major players operating in theglobal human insulin market include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Pfizer, Biocon, Wockhardt, MannKind Corporation, Tonghua Dongbao Pharmaceutical Co., Ltd., Medtronic, and Lupin. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Product Type
- Pens
- Syringes
- Others
By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
By Type Of Insulin
- Rapid-acting insulin
- Short-acting insulin
- Intermediate-acting insulin
- Others
By Distribution Channel
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- Pfizer
- Biocon
- Wockhardt
- MannKind Corporation
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Medtronic
- Lupin
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: IVF SERVICES MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Fresh IVF Cycle
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Thawed IVF Cycle
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Donor Egg IVF Cycle
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: IVF SERVICES MARKET, BY END USER
5.1. Market Overview
5.1.1 Market Size and Forecast, By End User
5.2. Fertility Clinics
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Hospitals
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Surgical Centers
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
5.5. Clinical Research Institutes
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, By Region
5.5.3. Market Share Analysis, By Country
CHAPTER 6: IVF SERVICES MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Type
6.2.3. Market Size and Forecast, By End User
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. IVF Services Market
6.2.5.1. Market Size and Forecast, By Type
6.2.5.2. Market Size and Forecast, By End User
6.2.6. Canada IVF Services Market
6.2.6.1. Market Size and Forecast, By Type
6.2.6.2. Market Size and Forecast, By End User
6.2.7. Mexico IVF Services Market
6.2.7.1. Market Size and Forecast, By Type
6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Type
6.3.3. Market Size and Forecast, By End User
6.3.4. Market Size and Forecast, By Country
6.3.5. France IVF Services Market
6.3.5.1. Market Size and Forecast, By Type
6.3.5.2. Market Size and Forecast, By End User
6.3.6. Germany IVF Services Market
6.3.6.1. Market Size and Forecast, By Type
6.3.6.2. Market Size and Forecast, By End User
6.3.7. Italy IVF Services Market
6.3.7.1. Market Size and Forecast, By Type
6.3.7.2. Market Size and Forecast, By End User
6.3.8. Spain IVF Services Market
6.3.8.1. Market Size and Forecast, By Type
6.3.8.2. Market Size and Forecast, By End User
6.3.9. UK IVF Services Market
6.3.9.1. Market Size and Forecast, By Type
6.3.9.2. Market Size and Forecast, By End User
6.3.10. Rest of Europe IVF Services Market
6.3.10.1. Market Size and Forecast, By Type
6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Type
6.4.3. Market Size and Forecast, By End User
6.4.4. Market Size and Forecast, By Country
6.4.5. China IVF Services Market
6.4.5.1. Market Size and Forecast, By Type
6.4.5.2. Market Size and Forecast, By End User
6.4.6. Japan IVF Services Market
6.4.6.1. Market Size and Forecast, By Type
6.4.6.2. Market Size and Forecast, By End User
6.4.7. India IVF Services Market
6.4.7.1. Market Size and Forecast, By Type
6.4.7.2. Market Size and Forecast, By End User
6.4.8. South Korea IVF Services Market
6.4.8.1. Market Size and Forecast, By Type
6.4.8.2. Market Size and Forecast, By End User
6.4.9. Australia IVF Services Market
6.4.9.1. Market Size and Forecast, By Type
6.4.9.2. Market Size and Forecast, By End User
6.4.10. Rest of Asia-Pacific IVF Services Market
6.4.10.1. Market Size and Forecast, By Type
6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Type
6.5.3. Market Size and Forecast, By End User
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil IVF Services Market
6.5.5.1. Market Size and Forecast, By Type
6.5.5.2. Market Size and Forecast, By End User
6.5.6. South Africa IVF Services Market
6.5.6.1. Market Size and Forecast, By Type
6.5.6.2. Market Size and Forecast, By End User
6.5.7. Saudi Arabia IVF Services Market
6.5.7.1. Market Size and Forecast, By Type
6.5.7.2. Market Size and Forecast, By End User
6.5.8. Rest of LAMEA IVF Services Market
6.5.8.1. Market Size and Forecast, By Type
6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Mayo Clinic Fertility Center
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Shady Grove Fertility Center
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Reproductive Medicine Associates
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Boston IVF, LLC.
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Colorado Center For Reproductive Medicine
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Pacific Fertility Center
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Houston Fertility Institute
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Columbia University Fertility Center
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Cleveland Clinic Fertility Center
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Fertility Centers of Illinois
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
TABLE 1. GLOBAL HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 2. HUMAN INSULIN MARKET FOR PENS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. HUMAN INSULIN MARKET FOR SYRINGES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. HUMAN INSULIN MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. GLOBAL HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 6. HUMAN INSULIN MARKET FOR TYPE 1 DIABETES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. HUMAN INSULIN MARKET FOR TYPE 2 DIABETES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. HUMAN INSULIN MARKET FOR GESTATIONAL DIABETES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. GLOBAL HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 10. HUMAN INSULIN MARKET FOR RAPID-ACTING INSULIN, BY REGION, 2024 - 2033 ($BILLION)
TABLE 11. HUMAN INSULIN MARKET FOR SHORT-ACTING INSULIN, BY REGION, 2024 - 2033 ($BILLION)
TABLE 12. HUMAN INSULIN MARKET FOR INTERMEDIATE-ACTING INSULIN, BY REGION, 2024 - 2033 ($BILLION)
TABLE 13. HUMAN INSULIN MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. GLOBAL HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 15. HUMAN INSULIN MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 16. HUMAN INSULIN MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 17. HUMAN INSULIN MARKET FOR ONLINE PROVIDERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 18. HUMAN INSULIN MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 19. NORTH AMERICA HUMAN INSULIN MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 20. NORTH AMERICA HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 21. NORTH AMERICA HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 22. NORTH AMERICA HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 23. NORTH AMERICA HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 24. U.S. HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 25. U.S. HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 26. U.S. HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 27. U.S. HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 28. CANADA HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 29. CANADA HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 30. CANADA HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 31. CANADA HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 32. MEXICO HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 33. MEXICO HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 34. MEXICO HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 35. MEXICO HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 36. EUROPE HUMAN INSULIN MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 37. EUROPE HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 38. EUROPE HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 39. EUROPE HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 40. EUROPE HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 41. GERMANY HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 42. GERMANY HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 43. GERMANY HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 44. GERMANY HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 45. FRANCE HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 46. FRANCE HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 47. FRANCE HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 48. FRANCE HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 49. UK HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 50. UK HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 51. UK HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 52. UK HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 53. ITALY HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 54. ITALY HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 55. ITALY HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 56. ITALY HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 57. SPAIN HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 58. SPAIN HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 59. SPAIN HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 60. SPAIN HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 61. REST OF EUROPE HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 62. REST OF EUROPE HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 63. REST OF EUROPE HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 64. REST OF EUROPE HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 65. ASIA-PACIFIC HUMAN INSULIN MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 66. ASIA-PACIFIC HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 67. ASIA-PACIFIC HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 68. ASIA-PACIFIC HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 69. ASIA-PACIFIC HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 70. JAPAN HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 71. JAPAN HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 72. JAPAN HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 73. JAPAN HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 74. CHINA HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 75. CHINA HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 76. CHINA HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 77. CHINA HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 78. INDIA HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 79. INDIA HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 80. INDIA HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 81. INDIA HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 82. AUSTRALIA HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 83. AUSTRALIA HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 84. AUSTRALIA HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 85. AUSTRALIA HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 86. SOUTH KOREA HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 87. SOUTH KOREA HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 88. SOUTH KOREA HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 89. SOUTH KOREA HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 90. REST OF ASIA-PACIFIC HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 91. REST OF ASIA-PACIFIC HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 92. REST OF ASIA-PACIFIC HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 93. REST OF ASIA-PACIFIC HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 94. LAMEA HUMAN INSULIN MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 95. LAMEA HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 96. LAMEA HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 97. LAMEA HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 98. LAMEA HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 99. BRAZIL HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 100. BRAZIL HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 101. BRAZIL HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 102. BRAZIL HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 103. SAUDI ARABIA HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 104. SAUDI ARABIA HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 105. SAUDI ARABIA HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 106. SAUDI ARABIA HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 107. SOUTH AFRICA HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 108. SOUTH AFRICA HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 109. SOUTH AFRICA HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 110. SOUTH AFRICA HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 111. REST OF LAMEA HUMAN INSULIN MARKET, BY PRODUCT TYPE, 2024 - 2033 ($BILLION)
TABLE 112. REST OF LAMEA HUMAN INSULIN MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 113. REST OF LAMEA HUMAN INSULIN MARKET, BY TYPE OF INSULIN, 2024 - 2033 ($BILLION)
TABLE 114. REST OF LAMEA HUMAN INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
TABLE 115. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 116. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 117. ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 118. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 119. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 120. SANOFI: KEY EXECUTIVES
TABLE 121. SANOFI: COMPANY SNAPSHOT
TABLE 122. SANOFI: OPERATING SEGMENTS
TABLE 123. SANOFI: PRODUCT PORTFOLIO
TABLE 124. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 125. NOVO NORDISK A/S: KEY EXECUTIVES
TABLE 126. NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 127. NOVO NORDISK A/S: OPERATING SEGMENTS
TABLE 128. NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 129. NOVO NORDISK A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 130. PFIZER: KEY EXECUTIVES
TABLE 131. PFIZER: COMPANY SNAPSHOT
TABLE 132. PFIZER: OPERATING SEGMENTS
TABLE 133. PFIZER: PRODUCT PORTFOLIO
TABLE 134. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 135. BIOCON: KEY EXECUTIVES
TABLE 136. BIOCON: COMPANY SNAPSHOT
TABLE 137. BIOCON: OPERATING SEGMENTS
TABLE 138. BIOCON: PRODUCT PORTFOLIO
TABLE 139. BIOCON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 140. WOCKHARDT: KEY EXECUTIVES
TABLE 141. WOCKHARDT: COMPANY SNAPSHOT
TABLE 142. WOCKHARDT: OPERATING SEGMENTS
TABLE 143. WOCKHARDT: PRODUCT PORTFOLIO
TABLE 144. WOCKHARDT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 145. MANNKIND CORPORATION: KEY EXECUTIVES
TABLE 146. MANNKIND CORPORATION: COMPANY SNAPSHOT
TABLE 147. MANNKIND CORPORATION: OPERATING SEGMENTS
TABLE 148. MANNKIND CORPORATION: PRODUCT PORTFOLIO
TABLE 149. MANNKIND CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 150. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
TABLE 151. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 152. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
TABLE 153. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 154. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 155. MEDTRONIC: KEY EXECUTIVES
TABLE 156. MEDTRONIC: COMPANY SNAPSHOT
TABLE 157. MEDTRONIC: OPERATING SEGMENTS
TABLE 158. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 159. MEDTRONIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 160. LUPIN: KEY EXECUTIVES
TABLE 161. LUPIN: COMPANY SNAPSHOT
TABLE 162. LUPIN: OPERATING SEGMENTS
TABLE 163. LUPIN: PRODUCT PORTFOLIO
TABLE 164. LUPIN: KEY STRATEGIC MOVES AND DEVELOPMENTS
FIGURE 1. GLOBAL HUMAN INSULIN MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF HUMAN INSULIN MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN HUMAN INSULIN MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHUMAN INSULIN MARKET
FIGURE 10. GLOBAL HUMAN INSULIN MARKET SEGMENTATION, BY PRODUCT TYPE
FIGURE 11. HUMAN INSULIN MARKET FOR PENS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. HUMAN INSULIN MARKET FOR SYRINGES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. HUMAN INSULIN MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. GLOBAL HUMAN INSULIN MARKET SEGMENTATION, BY INDICATION
FIGURE 15. HUMAN INSULIN MARKET FOR TYPE 1 DIABETES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. HUMAN INSULIN MARKET FOR TYPE 2 DIABETES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. HUMAN INSULIN MARKET FOR GESTATIONAL DIABETES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 18. GLOBAL HUMAN INSULIN MARKET SEGMENTATION, BY TYPE OF INSULIN
FIGURE 19. HUMAN INSULIN MARKET FOR RAPID-ACTING INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 20. HUMAN INSULIN MARKET FOR SHORT-ACTING INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 21. HUMAN INSULIN MARKET FOR INTERMEDIATE-ACTING INSULIN, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. HUMAN INSULIN MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 23. GLOBAL HUMAN INSULIN MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
FIGURE 24. HUMAN INSULIN MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 25. HUMAN INSULIN MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 26. HUMAN INSULIN MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 27. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 28. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 29. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 30. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 31. COMPETITIVE DASHBOARD
FIGURE 32. COMPETITIVE HEATMAP: HUMAN INSULIN MARKET
FIGURE 33. TOP PLAYER POSITIONING, 2023
FIGURE 34. ELI LILLY AND COMPANY: NET SALES, 2021-2023 ($BILLION)
FIGURE 35. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 36. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 37. SANOFI: NET SALES, 2021-2023 ($BILLION)
FIGURE 38. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 39. SANOFI: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 40. NOVO NORDISK A/S: NET SALES, 2021-2023 ($BILLION)
FIGURE 41. NOVO NORDISK A/S: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 42. NOVO NORDISK A/S: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 43. PFIZER: NET SALES, 2021-2023 ($BILLION)
FIGURE 44. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 45. PFIZER: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 46. BIOCON: NET SALES, 2021-2023 ($BILLION)
FIGURE 47. BIOCON: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 48. BIOCON: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 49. WOCKHARDT: NET SALES, 2021-2023 ($BILLION)
FIGURE 50. WOCKHARDT: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 51. WOCKHARDT: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 52. MANNKIND CORPORATION: NET SALES, 2021-2023 ($BILLION)
FIGURE 53. MANNKIND CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 54. MANNKIND CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 55. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 56. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 57. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 58. MEDTRONIC: NET SALES, 2021-2023 ($BILLION)
FIGURE 59. MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 60. MEDTRONIC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 61. LUPIN: NET SALES, 2021-2023 ($BILLION)
FIGURE 62. LUPIN: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 63. LUPIN: REVENUE SHARE, BY REGION, 2023 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security